Literature DB >> 3977647

Carbamazepine toxicity induced by concurrent erythromycin therapy.

E Carranco, J Kareus, S Co, V Peak, S Al-Rajeh.   

Abstract

We describe a 41-year-old woman receiving carbamazepine for epilepsy, in whom concurrent erythromycin stearate administration led to carbamazepine toxicity, including inappropriate antidiuretic hormone syndrome. We review the literature on erythromycin-carbamazepine interaction and discuss the mechanism for such interaction.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3977647     DOI: 10.1001/archneur.1985.04060020105023

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  11 in total

1.  Acute drug prescribing to children on chronic antiepilepsy therapy and the potential for adverse drug interactions in primary care.

Authors:  Philipp H Novak; Suzie Ekins-Daukes; Colin R Simpson; Robert M Milne; Peter Helms; James S McLay
Journal:  Br J Clin Pharmacol       Date:  2005-06       Impact factor: 4.335

2.  Severe carbamazepine toxicity induced by concurrent erythromycin therapy.

Authors:  C R Mota; C Carvalho; C Mota; P Ferreira; A Vilarinho; E Pereira
Journal:  Eur J Pediatr       Date:  1996-04       Impact factor: 3.183

3.  Interactions Between Antiepileptic and Antibiotic Drugs: A Systematic Review and Meta-Analysis with Dosing Implications.

Authors:  Carla Carnovale; Marco Pozzi; Faizan Mazhar; Giulia Mosini; Marta Gentili; Gabriëlla G A M Peeters; Emilio Clementi; Sonia Radice
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447

Review 4.  Drug interactions that matter. A critical reappraisal.

Authors:  G T McInnes; M J Brodie
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

Review 5.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 6.  Macrolide antibacterials. Drug interactions of clinical significance.

Authors:  N A von Rosensteil; D Adam
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606

7.  Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite.

Authors:  N Barzaghi; G Gatti; F Crema; M Monteleone; C Amione; L Leone; E Perucca
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

Review 8.  Pharmacokinetic drug interactions of macrolides.

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

Review 9.  Carbamazepine toxicity and poisoning. Incidence, clinical features and management.

Authors:  L Durelli; U Massazza; R Cavallo
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Mar-Apr

Review 10.  Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

Authors:  F Pea; M Furlanut
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.